Santa Clara, California-based Agilent Technologies, Inc. (A) provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. Valued at a market cap of $40.8 billion, the company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Companies with a market cap of $10 billion or more are typically referred to as “large-cap stocks.” A fits perfectly into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the diagnostics and research industry.
Despite its strength, shares of Agilent are down 11.6% from its 52-week high of $163.75, touched on Aug. 27. Moreover, A has risen 6.8% over the past three months and has outperformed the Dow Jones Industrial Average ($DOWI), which has grown 3% during the same period.
Zooming out a little further, the scenario remains the same. Over the past 52 weeks, A has surged 14.7%, slightly outpacing DOWI’s 14.6% gain.
Agilent has been trading above its 200-day moving average since July and also above its 50-day moving average since May, indicating bullish momentum.
On Aug. 26, A stock rose marginally following the release of its better-than-expected Q3 2026 earnings. The company’s revenue for the quarter amounted to $1.9 billion and topped the consensus estimates. Moreover, its adjusted EPS for the period came in at $1.62, also coming in on top of Wall Street’s forecasts. The company expects revenue in the range of $1.98 billion to $2 billion for the fiscal fourth quarter. Moreover, it expects full-year earnings in the range of $6.18 to $6.21 per share, with revenue ranging from $7.49 billion to $7.51 billion.
When stacked against its peer, IQVIA Holdings Inc. (IQV), A has underperformed. Over the past year, IQV stock has grown 35.5%.
Sentiment on A remains moderately optimistic. Among the 20 analysts covering the stock, the consensus rating is a “Moderate Buy.” Its mean price target of $174.84 suggests 20.8% upside from current levels.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.